v Share Your Health

Gene Sequencing Yields Picture of Human Gut

THURSDAY, March 4 (HealthDay News) — Researchers have succeeded in sequencing 3.3 million genes from organisms residing in the human gut.

And it appears that each person harbors at least 160 species of bacteria in their gut, far more than originally estimated, according to a paper appearing in the March 4 issue of Nature. The research was led by researchers in China as part of the MetaHIT (Metagenomics of the Human Intestinal Tract) project.

Although this is just the first tiny dent in a mountain of work to be done, the findings should help experts understand both human health and human illness better.

“This is so rich. It could help in so many different ways. It could help us understand diseases like inflammatory bowel disease [IBD], Crohn’s and ulcerative colitis. It could help us with problems like malnutrition and obesity. It could help us understand many different metabolic problems from liver disease to kidney to heart disease,” said Dr. Martin Blaser, chairman of the department of medicine at New York University Langone Medical Center and a professor of microbiology at New York University School of Medicine in New York City. “This is really a landmark study.”

Humans coexist peacefully and sometimes not so peacefully with legions of microorganisms in their gut. An estimated 100 trillion cells make up these microbes. That’s 10 times the number of human cells in the body.

“There are symbiotic relationships with these bacteria,” explained Dr. Brian Currie, vice president and medical director for research at Montefiore Medical Center in New York City. “They make substances we need … and there’s a body of literature that suggests that the interaction with these bacteria may have something to do with immune modulation as well. It’s a largely unexplored area.”

Another expert, Jeffrey Cirillo, a professor of microbial and molecular pathogenesis at the Texas A&M Health Science Center College of Medicine in College Station, said that, “basically the gut functions properly because of the large amount of bacteria that are present within it.”

“In other words, rather than the gut being controlled by us, it’s actually controlled by the bacteria present in it,” he said. “There’s almost a limitless number of diseases and health characteristics that are affected by what we eat and how it gets digested, and the microflora that are present basically determine how that gets handled. It’s a critical component of health overall.”

This research team was able to identify and sequence 3.3 million microbe genes from fecal samples taken from 124 Europeans. This is 150 times more microbial genes than human genes.

The participants, from Spain and Denmark, were either healthy or had inflammatory bowel disease.

More than 99 percent of the genes were bacterial, representing up to 1,150 different bacterial species.

Although most of the 3.3 million genes must be shared among individuals, the study authors were only able to show that 38 percent of the genes seen in each individual were shared with at least half of the other individuals sampled.

And while much has been made of “good” bacteria vs. “bad” bacteria in people’s bodies, the organisms involved may not be either.

“This may have to do more with proportions. Maybe there is a certain ecological balance of certain kinds of organisms, and disease is not necessarily due to having bad bacteria but an imbalance,” Blaser said. “When you take a census and you have schoolteachers, policemen, insurance brokers, etc. That’s kind of healthy. But let’s say you took a census and everybody was a Wall Street stockbroker. That may be less healthy. The proportions of the different kinds of organisms that are present could be more important.”

For instance, patients with inflammatory bowel disease had, on average, 25 percent fewer genes than healthy individuals, indicating that patients suffering from IBD have less diversity in their guts.

“We know that some of these functions are critical for human health and well-being, and these are the first initial baby steps to fully characterize what those are, to get a handle on the diversity,” added Dale Hedges, an assistant professor at the John P. Hussman Institute for Human Genomics and assistant director of the Center for Genome Technology at the University of Miami Miller School of Medicine. “As we start to get a better grasp of the genetic diversity in our gut biome, we can start to ask questions about the relationship between the genetic diversity that’s existing in our microbiome internally and our susceptibility to different diseases and what the interaction is.”

Cirillo is enthusiastic. “A picture is worth a thousand words, and this gives us a picture of what’s going on in the gut,” he said.

More information

Visit the International Human Microbiome Consortium for more on this type of research.

By Amanda Gardner
HealthDay Reporter

SOURCES: Martin Blaser, chairman, department of medicine, Langone Medical Center, and professor, microbiology, New York University School of Medicine, New York City; Dale Hedges, Ph.D., assistant professor, John P. Hussman Institute for Human Genomics, and assistant director, Center for Genome Technology, University of Miami Miller School of Medicine; Brian Currie, M.D., vice president and medical director, research, Montefiore Medical Center, New York City; Jeffrey Cirillo, Ph.D., professor, microbial and molecular pathogenesis, Texas A&M Health Science Center College of Medicine, College Station; March 4, 2010, Nature

Last Updated: March 04, 2010

Copyright © 2010 HealthDay. All rights reserved.

Gut Bacteria May Spur Obesity, Research Suggests

THURSDAY, March 4 (HealthDay News) — Intestinal bacteria may contribute to obesity and metabolic syndrome, a new study in mice suggests.

“It has been assumed that the obesity epidemic in the developed world is driven by an increasingly sedentary lifestyle and the abundance of low-cost, high-calorie foods. However, our results suggest that excess caloric consumption is not only a result of undisciplined eating but that intestinal
bacteria contribute to changes in appetite and metabolism,” senior study author Andrew Gewirtz, an associate professor of pathology and laboratory medicine at Emory University School of Medicine, said in a university news release.

He and his colleagues found that increased appetite and insulin resistance can be transferred from one mouse to another via intestinal bacteria. The findings are published online March 4 in the journal Science.

It’s believed that intestinal bacteria populations in people are acquired at birth from family members and are relatively stable. However, they can be affected by diet and antibiotics.

“Previous research has suggested that bacteria can influence how well energy is absorbed from food, but these [new] findings demonstrate that intestinal bacteria can actually influence appetite,” Gewirtz explained.

He said the findings from mice suggest “that it’s possible to ‘inherit’ metabolic syndrome through the environment, rather than genetically. Do obese children get that way because of bad parenting? Maybe bacteria that increase appetite are playing a part.”

A gene called toll-like receptor 5 (TLR5) plays an important role in controlling intestinal bacteria. Gewirtz and colleagues plan to investigate TLR5 variations in humans and how bacteria in TLR5-deficient mice influence appetite and metabolism.

More information

The American Academy of Family Physicians has more about metabolic syndrome.

— Robert Preidt

SOURCE: Emory University, news release, March 4, 2010

Last Updated: March 04, 2010

Copyright © 2010 HealthDay. All rights reserved.

Scientists Discover How Chemo Can Make Women Infertile

MONDAY, Sept. 28 (HealthDay News) — Italian researchers say they have identified the mechanism by which chemotherapy can rob a woman of her ability to have children.

Intriguingly, the scientists also found that another anti-cancer drug might counteract the negative effects of the chemotherapy drug cisplatin.

The finding, demonstrated in mice and reported in the Sept. 27
online edition of Nature Medicine, raises the hope that there might be a way to protect a woman’s fertility while she undergoes treatment for cancer but, the authors stressed, this is still a long way off.

“The extension of these findings to patients and the design of clinical trials is likely to require the development of targeted drug delivery strategies to avoid any potential interference with anti-cancer systemic therapy,” explained study author Stefania Gonfloni, of the department of biology at the University of Rome.

“I think it’s a great idea. They found a pathway that can be used as a marker to detect which drug would produce cell death as a result of chemotherapy, and they found a repair effect of a drug,” said Dr. George Attia, an associate professor of reproductive endocrinology and infertility at the University of Miami Miller School of Medicine. “[But] it’s very basic science research. It’s still early.”

Because chemotherapy affects the egg cells of the ovary, women often end up with ovarian failure and infertility as a result of cancer treatment.

“We frequently deal with women of childbearing age, and there’s a lot of concern about fertility preservation although as women get older, the chemo induces menopause,” said Dr. Igor Astsaturov, an assistant professor of medical oncology at Fox Chase Cancer Center in Philadelphia. “The standard approach now is egg collection [storing eggs for later use].”

Chemotherapy can also cause genetic defects in offspring. In particular, cisplatin, which was studied in this trial, causes specific types of chromosomal damage.

Cisplatin is primarily usually used to treat ovarian cancer, Attia noted.

In this study, Gonfloni and her colleagues showed that cisplatin promotes the death of oocytes, or female germ cells, by way of the c-Abl enzyme, a protein that, when mutated, can also cause chronic myeloid leukemia (CML).

But targeting the enzyme with imatinib (Gleevec), a drug used to treat CML, protected the oocytes from the ill effects of cisplatin.

“These results raise the possibility of protecting ovarian function during cancer treatments, thereby preserving the fertility in female cancer survivors,” Gonfloni added.

But how to use one drug without compromising the other?

“First, we have to show that imatinib can be used to prevent chemotherapy-induced ovarian toxicity without interfering with anti-cancer treatments,” Gonfloni said. “In other words, we have to prove that tumor-bearing laboratory animals can be cured with a combined cisplatin and imatinib treatment, while at the same time preserving fertility,” she explained.

“Then, for any clinical implications, it will be very important to prove the same protective effect of a specific dosage of imatinib on human oocytes cultured and challenged with chemotherapeutic drugs in vitro,” she added.

And preserving fertility is not always the right thing, Astsaturov said.

“Chemotherapy induces menopause in some hormone-dependent cancers. It has a beneficial effect because it’s withdrawing the stimulants for the cancer cells. Menopause is contributing to the cure,” he said. “It’s still debated whether we should preserve menstrual function at all costs.”

More information

Visit Cancer Research UK for more on chemotherapy and fertility.

By Amanda Gardner
HealthDay Reporter

SOURCES: Stefania Gonfloni, Ph.D., department of biology, University of Rome, Italy; George Attia, M.D., associate professor, reproductive endocrinology and infertility, University of Miami Miller School of Medicine; Igor Astsaturov, M.D., assistant professor, medical oncology, Fox Chase Cancer Center, Philadelphia; Sept. 27, 2009, Nature Medicine, online

Last Updated: Sept. 28, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Stem Cells Spur New Eggs in Ovaries of Adult Mice

SUNDAY, April 12 (HealthDay News) — Researchers in China have demonstrated that female ovaries may be capable of producing new eggs in adulthood and subsequently producing offspring.

That runs counter to the long-held belief that female mammals, including humans, are born with a finite number of the eggs (oocytes) needed to produce offspring.

According to study senior author Ji Wu, a professor at Shanghai Jiao
Tong University, the findings may lead to techniques for the “generation of new oocytes to postpone normal or premature ovarian failure or for the treatment of infertility.”

Paul Sanberg, a stem cell researcher and distinguished professor of neurosurgery and director of the University of South Florida Center for Aging and Brain Repair in Tampa, called the study “fascinating.”

“These stem cells are continuous,” explained Sanberg, who was not involved in the research. “They were still around through life and actually transformed to make oocytes. Then they were transplanted into infertile females and produced offspring.”

Could doctors someday use stem cells to help adult women produce brand-new oocytes? One reproductive medicine expert isn’t sure.

The new finding is “very, very exciting and opens up a big area of discussion,” said Dr. George Attia, associate professor of reproductive endocrinology and infertility at the University of Miami Miller school of Medicine. “If it would ever come to fruition in humans, I really don’t know. It’s far, far out there,” he said.

Another expert agreed.

“It’s a cute experiment, but I don’t think it’s going to have anything to do with humans,” said Dr. Darwin J. Prockop, director of the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White. “There are too many steps, too many things could go wrong.”

But the findings, published online April 12 in Nature Cell Biology, could still have interesting implications for future stem cell and other research, Prockop added. “Any new kind of cell is interesting,” he said.

For years, scientists had believed that the capability to produce oocytes was lost in most mammalian species at birth.

That line of thought was tested with the recent discovery of actively dividing germ cells (those that give rise to sexual reproduction) in the ovaries of both juvenile and adult mice. The presence of these germ cells could indicate reproductive capability.

Still, researchers disagreed as to whether female germline stem cells (FGSCs) do exist in mammalian ovaries after birth.

So, the Chinese team isolated active female FGSCs from adult and five-day-old mice. They say that they were able to generate new FGSC lines that proliferated even after being cultured multiple times.

These FGSCs restored fertility (by producing new oocytes) when transplanted into the ovaries of female mice that were previously rendered infertile by chemotherapy.

The females then gave birth to normal, young mice.

Even if the breakthrough could apply to humans, it likely would only apply to younger women experiencing infertility, Attia said. “Pregnancy is a heavy load on the human body. A 60-year-old might not be able to be pregnant,” he noted.

In other stem cell news, researchers reporting Sunday in the journal Nature Biotechnology said that they were able to use bits of genetic material called microRNA to revert adult mouse cells back into embryonic cells.

These new embryonic cells are, like stem cells, capable of transforming into multiple different types of tissue.

Currently, retroviruses and genes are used to complete this transformation, but this carries the risk of cancer and other problems. Using microRNAs, which regulate gene expression, would be a potentially safer method, said researchers from the University of California, San Francisco.

More information

There’s more on stem cells at the U.S. National Institutes of Health.

SOURCES: Ji Wu, Ph.D., professor, Shanghai Jiao Tong University, Shanghai, China; Darwin J. Prockop, M.D., Ph.D., director, Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White, and Stearman Chair in Genomic Medicine and professor of molecular and cellular medicine, Texas A&M Health Science Center College of Medicine; George Attia, M.D., associate professor, reproductive endocrinology and infertility, University of Miami Miller School of Medicine; Paul Sanberg, Ph.D., D.Sc., distinguished professor, neurosurgery and director, University of South Florida Center for Aging and Brain Repair, Tampa; April 12, 2009, Nature Cell Biology, Nature Biotechnology

By Amanda Gardner
HealthDay Reporter

 Last Updated: April 13, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Weight Loss Helps Incontinence

WEDNESDAY, Jan. 28 (HealthDay News) — If you’re among the millions of women who suffer from urinary incontinence, losing weight might just ease your symptoms, a new study suggests.

Published in the Jan. 29 issue of the New England Journal of Medicine, the study found that when women lost about 8 percent of their body weight — an average of 17 pounds for this group — the frequency of incontinence episodes dropped by almost half.


“Weight is one of the biggest risk factors for developing incontinence and for worsening incontinence,” said study author Dr. Leslee Subak, an associate professor in the departments of obstetrics, gynecology, reproductive sciences, urology and epidemiology and biostatistics at the University of California, San Francisco.

More than 13 million American women have urinary incontinence problems, according to background information in the study. Observational studies have found an association between extra weight and incontinence, and other research has suggested that losing weight might be beneficial for relieving incontinence symptoms.

To confirm these findings, Subak and her colleagues recruited 338 women from Rhode Island and Alabama. The women had to be at least 30, with a body-mass index (BMI) between 25 and 50. A BMI over 25 is considered overweight and over 30 is obese, according to the National Institutes of Health. All of the women experienced at least 10 incontinence episodes in a seven-day period.

Two-thirds of the women were randomly assigned to the intervention group, which included diet, exercise and behavior modification, while the remaining one-third (the control group) received four educational sessions about weight loss, healthful eating and physical activity. All of the women received a self-help booklet with tips for improving their urinary incontinence.

The intervention group met for one hour every week for six months and were put on a structured protocol, including diet and exercise, designed to help them lose between 7 percent and 9 percent of their starting weight.

On average, the intervention group lost 8 percent of their body weight, or about 17 pounds each. The control group lost 1.6 percent of their body weight, or a little more than 3 pounds each.

After six months, the weekly number of incontinence episodes dropped by 47 percent for those in the intervention group compared to 28 percent in the control group. The intervention group also reported fewer episodes of stress incontinence — that’s incontinence that occurs due to extra pressure from laughing, coughing or sneezing. This group did not see improvement in urge incontinence — that’s the feeling of a sudden need to urinate.

“The reduced pressure from weight loss causes reduced pressure on the bladder,” Subak explained.

She said these findings confirm that weight loss can be considered a first-line treatment for women with incontinence.

“The weight we carry around affects our bodies in so many different ways,” said Dr. Janet Tomezsko, chief of the section of urogynecology at Northwestern Memorial Hospital in Chicago. “And, the more overweight you are, the more you have to lose to make an impact, but you can make an impact. It’s not an easy thing to do, but I think we’re going to see more and more programs that address weight loss, exercise and pelvic health.”

More information

To learn more about incontinence in women, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

SOURCES: Leslee Subak, M.D., associate professor, departments of obstetrics, gynecology, reproductive sciences, urology and epidemiology and biostatistics; University of California, San Francisco; Janet Tomezsko, M.D., chief, urogynecology and pelvic reconstructive surgery, department of obstetrics and gynecology, Northwestern Memorial Hospital, Chicago; Jan. 29, 2009, New England Journal of Medicine

By Serena Gordon
HealthDay Reporter

Last Updated: Jan. 28, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Female Incontinence a Prevalent Problem

TUESDAY, Sept. 16 (HealthDay News) — Almost 25 percent of American women have a pelvic floor disorder, such as urinary incontinence, fecal incontinence or pelvic organ prolapse, according to new research.

“This study showed that pelvic floor disorders are exceedingly common in women in the United States,” said the study’s lead author, Dr. Ingrid Nygaard, a professor in the division of urogynecology and pelvic reconstructive surgery in the department of obstetrics and
gynecology at the University of Utah School of Medicine.

And, though these disorders are prevalent, women don’t always bring them up with their doctors, said Nygaard. “Pelvic floor disorders are not talked about often, and women are often too embarrassed to bring them up” with their doctors, she said.

Said Dr. Victor Nitti, vice chairman of urology at New York University Langone Medical Center: “I don’t think there’s any question that pelvic floor disorders are underreported. Some women are embarrassed, and some think they’re a normal part of aging. Either way, it’s not something women will often report spontaneously.”

The new study, published in the Sept. 17 issue of the Journal of the American Medical Association, reviewed data from almost 2,000 women over the age of 20 who had participated in the 2005-06 National Health and Nutrition Examination Survey. This study group is considered to be representative of the U.S. population. None of the women included in the data analysis was pregnant at the time of the study.

The women were interviewed at home and underwent a physical in a mobile examination center. Urinary incontinence was diagnosed based on scoring more than “three” on an incontinence severity index. Fecal incontinence was diagnosed if women reported having at least once monthly leakage of stool. And pelvic organ prolapse was diagnosed if women reported feeling a bulge inside or outside of the vagina. (Pelvic organ prolapse occurs when one of the pelvic organs, such as the uterus, drops and presses on the vagina.)

Overall, the researchers found that 23.7 percent of women experienced at least one pelvic floor disorder. Almost 16 percent of the women reported urinary incontinence, 9 percent experienced fecal incontinence, and 2.9 percent reported pelvic organ prolapse.

Nygaard pointed out that this study looked at moderate to severe incontinence. She said it’s quite common for women to leak small amounts of urine while laughing or sneezing, but that’s not what was studied here.

Older women were most likely to report a pelvic floor disorder, with almost 50 percent of those 80 and older reporting at least one pelvic floor disorder, compared to just 10 percent of women between 20 and 39 years old.

Having been pregnant increased the odds of pelvic floor disorders, and, with each pregnancy, the likelihood of incontinence or prolapse rose. Being overweight or obese also increased the risk of pelvic floor disorders, according to the study.

Both Nygaard and Nitti said that effective treatments are available for women with pelvic floor disorders. Nygaard recommended that women start with the most conservative treatment options, such as pelvic muscle strengthening and behavioral therapy. Surgery, which can be effective for certain problems, is usually reserved as a last option, she said.

“The most important thing women need to realize is that they’re not alone. Pelvic floor disorders aren’t dangerous and are treatable,” said Nygaard.

Nitti added: “If you have any symptoms related to any of these problems, and they bother you, you shouldn’t be embarrassed to bring it to the attention of your health-care providers. All are, in one way or another, treatable, particularly at the early stages.”

More information

Learn more about pelvic floor disorders from the National Institute of Child Health and Human Development.

SOURCES; Ingrid Nygaard, M.D., professor, division of urogynecology and pelvic reconstructive surgery, department of obstetrics and gynecology, University of Utah School of Medicine, Salt Lake City; Victor Nitti, M.D., vice chairman, urology, and professor, New York University Langone Medical Center, New York City; Sept. 17, 2008, Journal of the American Medical Association

By Serena Gordon
HealthDay Reporter

Last Updated: Sept. 16, 2008

Copyright © 2008 ScoutNews, LLC. All rights reserved.

New Guidelines Issued for Management of IBS

THURSDAY, Dec. 18 (HealthDay News) — A leading organization of gastroenterologists has released new guidelines on the management of irritable bowel syndrome (IBS).

The guidelines, issued by the American College of Gastroenterology and published in the January issue of The American Journal of Gastroenterology, essentially replace a 2002 document.

“The world of IBS is changing quickly because of more therapies and an increased awareness. It is considered a ‘real disease,’
” said Dr. Lawrence Brandt, chairman of the group’s IBS task force and chief of gastroenterology at Montefiore Medical Center in New York City. “A lot of new drugs are being developed, and a lot of work still needs to be done, but there’s enough new information since the last time.”

“From the practitioner’s standpoint, this doesn’t change much about practice and there’s not that much information that’s new, although it is thorough and helpful,” said Dr. Benjamin D. Havemann, an assistant professor of internal medicine at the Texas A&M Health Science Center College of Medicine and director of gastroenterology for the Round Rock University Medical Campus of Scott & White Hospital. “It shows what little has transpired [in terms of new treatments] in the last few years. Some of the breakthroughs we had have been withdrawn or are under strict control.”

“One powerful piece of information is that extensive work-ups are unhelpful,” Havemann said. “It makes sense to me that in the absence of alarm symptoms, the benefit of even basic blood work and other tests is in doubt.”

An estimated 7 percent to 10 percent of people have IBS, which can involve abdominal pain, bloating and other discomfort, including constipation and diarrhea. IBS affects both quality of life and productivity for millions of people.

Most IBS treatments relieve symptoms rather than resolve the condition itself.

The new guidelines encompass existing evidence on conventional treatments for IBS as well as new therapies (probiotics, for example) and alternative therapies (acupuncture and more). In summary, the updated guidelines say:

    Fiber products — including psyllium, anti-spasmodic medications and peppermint oil — may be effective, at least in some people. “The evidence is poor, but some patients say they feel better,” Brandt said. He cautioned that fiber should be used carefully in people with narrowed colons.
    More data is needed on probiotics, live microorganisms (usually bacteria) similar to the “good” organisms found normally in the gut. “This is a very hot topic but an exceedingly complicated subject,” Brandt said. Researchers and practitioners need to consider the species of bacteria used, how many species, and dosages.
    Non-absorbable antibiotics — those targeted to the gut only, such as rifaximin (Xifaxan) — also seem to help some people, especially those who have “diarrhea-predominant IBS.” Brandt said that “the data is not great, but some patients swear they’re helping them dramatically.”
    Tricyclic antidepressants as well as the antidepressants known as selective serotonin reuptake inhibitors (SSRIs) benefit a broad range of people with IBS. This is backed up by quality studies, although with small numbers of participants, and could change as research on larger numbers of people is evaluated. Psychological counseling may also provide some relief.
    Selective C-2 chloride channel activators, notably lubiprostone (Amitiza), are effective for “constipation-predominant IBS.”
    5HT 3 antagonists such as alosetron (Lotronex) relieve symptoms of diarrhea but can cause constipation and colon ischemia, a restriction of blood flow.
    5HT 4 agonists, though effective against constipation, are not available in North America because of a heightened risk of cardiovascular problems.
    There is yet to be conclusive evidence on Chinese herbal mixtures, and the mixtures run the risk of causing liver failure and other problems. Differences in the content of compounds and the purity of ingredients complicate evaluation of benefits.
    Similarly, the evidence on acupuncture remains inconclusive.
    There is no evidence at this point that testing for food allergies or following diets that exclude certain foods alleviates IBS symptoms.
    Routine diagnostic testing for IBS is not recommended, although some testing should be performed in certain subgroups of patients.

Though comprehensive, the guidelines were criticized for not explaining what outside funding was used for in the development process. The document does disclose that support was received from Takeda Pharmaceutical Co. and Salix Pharmaceuticals, which make products targeted to IBS.

Dr. Mark Ebell, deputy editor of American Family Physician, said he would feel more comfortable if the guidelines had been “very clear about what support was provided and what they needed the support for: paying for literature searches, for staff. … It’s common to have support for guidelines. … I think it’s generally unintentional, but when we have a relationship, it creates the potential for problems.”

Ebell said that Brandt had relationships with pharmaceutical companies.

Brandt had a different view. “I don’t have any ties to industry that would have any relevance to this publication,” he said. “I don’t receive money directly from any company. I own no stock and, nor does my family, so this is a totally unbiased thing. I have no conflict of interest whatsoever, and I think that does it.”

Anne-Louise B. Oliphant, a spokeswoman for the American College of Gastroenterology, said: “No company was involved in any way in either structuring or completing the meta-analysis that forms the basis for the College’s evidence-based recommendations on IBS. Furthermore, no company was in any way involved in deciding who served on the task force or in any of its work.”

More information

To learn more about IBS, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases online.

SOURCES: Lawrence J. Brandt, M.D., chief, division of gastroenterology, Montefiore Medical Center, and professor of medicine and surgery, Albert Einstein College of Medicine, New York City; Mark H. Ebell, M.D., deputy editor, American Family Physician; Anne-Louise B. Oliphant, spokeswoman, American College of Gastroenterology, Bethesda, Md.; Benjamin D. Havemann, M.D., assistant professor, internal medicine, Texas A&M Health Science Center College of Medicine, and director, gastroenterology, Round Rock University Medical Campus, Scott & White Hospital; January 2009 The American Journal of Gastroenterology

By Amanda Gardner
HealthDay Reporter

Last Updated: Dec. 18, 2008

Copyright © 2008 ScoutNews, LLC. All rights reserved.